Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2025-07-16 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
董事会提名委员会关于第六届高级管理人员任职资格的审查意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from the Board Nomination Committee regarding the qualifications and appointment of senior management personnel and the board secretary. It references compliance with company law, stock exchange listing rules, and internal governance documents. There is no financial data, no mention of financial results, no audit information, or any report publication. The content focuses on management appointments and qualifications, which aligns with announcements about changes or appointments in senior management or board members. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and does not indicate it is a report or announcement of a report publication, so it is not RPA or RNS.
2025-07-16 Chinese
关于第六届董事会第一次会议决议的公告
Board/Management Information Classification · 100% confidence The document is an announcement of resolutions passed at the first meeting of the sixth board of directors of the company. It details the election of the chairman, appointment of senior management, and committee members. The content focuses on board and management changes rather than financial results or reports. The document length is relatively short (2774 characters) and it is a formal announcement of board decisions, not a full report or financial statement. Therefore, it fits the category of Board/Management Information (MANG).
2025-07-16 Chinese
2025年半年度业绩预告
Earnings Release Classification · 95% confidence The document is titled '2025 年半年度业绩预告' which translates to '2025 Half-Year Performance Forecast'. It provides preliminary profit estimates for the period January 1 to June 30, 2025, with explanations about the reasons for performance changes and a disclaimer that the data is preliminary and unaudited. It explicitly states that detailed financial data will be disclosed in the 2025 half-year report. The document is short (1402 characters) and serves as a performance forecast rather than a full interim report containing actual financial statements or substantive financial data. Therefore, it is a performance forecast announcement, which aligns with the category of Earnings Release (ER) as it announces key highlights of quarterly/periodical financial results. H1 2025
2025-07-14 Chinese
关于提前归还2023年度以简易程序向特定对象发行股票暂时补充流动资金的募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the early repayment of funds temporarily used from proceeds raised by a specific stock issuance to supplement working capital. It details the board meeting approval, the amount involved, and the repayment completion. The content focuses on capital usage and financing activities related to the company's fundraising proceeds. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. The document is a specific update on capital structure and fund usage, fitting the Capital/Financing Update category.
2025-07-02 Chinese
董事会秘书工作细则
Governance Information Classification · 95% confidence The document is titled as the "Board Secretary Work Rules" for a company, detailing the duties, qualifications, appointment, and responsibilities of the board secretary. It references company governance, legal compliance, and interaction with the stock exchange. There is no financial data, no report of financial results, no voting results, no announcement of a report publication, and no mention of any specific financial period or regulatory filing. The content is focused on governance practices and internal company rules related to the board secretary role. Therefore, this document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-06-30 Chinese
关于召开2025年第二次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice for convening the 2025 second extraordinary general meeting (临时股东会) of 特一药业集团股份有限公司. It includes information about the meeting date, time, venue, agenda items for shareholder voting, voting procedures including cumulative voting for board elections, registration details, and proxy authorization forms. The content focuses on the announcement and procedural details for the shareholder meeting rather than the meeting minutes, voting results, or any financial report. There is no financial data or earnings information, nor is it a transcript or presentation. It is not a report publication announcement since it contains substantive meeting details and instructions. The document fits the category of a formal notice to shareholders about an upcoming shareholders' meeting, which is best classified as a Proxy Solicitation & Information Statement (PSI).
2025-06-30 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.